Best of the Week
Most Popular
1. Climate Change Mass Extinction - Birds, Bees and Bugs: Going Going Gone - Richard_Mills
2.A Purrrfect Gold Price Setup! - Peter_Degraaf
3.Who Finances America's Borrowing? Recession Indicator for Independent Thinkers Part 2 - F_F_Wiley
4.America’s One-sided Domestic Financial War - Raymond_Matison
5.Gold Price Summer Doldrums - Zeal_LLC
6.Two Key Events Will Unleash Gold - Jim_Willie_CB
7.Billionaire Schools Teacher in NAFTA Trade Talks - Richard_Mills
8.Get Out Of Crypto Cannabis Bubble Before It Pops and Move Into Bargain Basement Miners - Jeb_Handwerger
9.Stock Market Could Pullback for 1-2 weeks, But Medium Term Bullish - Troy_Bombardia
10.G7 Chaos, Central Banks and US Fed Will Drive Stock Prices This Week - Chris_Vermeulen
Last 7 days
Gerald Celente: Why You Still Need Guns, Gold, and a Getaway Plan... - 23rd Jun 18
Cheap Gold Stocks Bottom Basing - 23rd Jun 18
A Trade War Won’t Be Good for the US Dollar - 23rd Jun 18
SPX/Gold, Long-term Yields & Yield Curve 3 Amigos Update - 22nd Jun 18
Gold - How Long Can This Last? - 22nd Jun 18
Dow Has Fallen 8 days in a Row. Medium-long Term Bullish for Stocks - 22nd Jun 18
Trouble Spotting Market Trends? This Can Help - 22nd Jun 18
Financial Markets Analysis and Trend Forecasts 2018 - A Message from Nadeem Walayat - 21st Jun 18
SPX Bouncing Above Support - 21st Jun 18
Things You Need To Know If You Want To Invest In Bitcoin Now - 21st Jun 18
The NASDAQ’s Outperformance vs. the Dow is Very Bullish - 21st Jun 18
Warning All Investors: Global Stock Market Are Shifting Away From US Price Correlation - 20th Jun 18
Gold GLD ETF Update… Breakdown ? - 20th Jun 18
Short-term Turnaround in Bitcoin Might Not Be What You Think - 19th Jun 18
Stock Market’s Short Term Downside Will be Limited - 19th Jun 18
Natural Gas Setup for 32% Move in UGAZ Fund - 19th Jun 18
Magnus Collective To Empower Automation And Artificial Intelligence - 19th Jun 18
Trump A Bull in a China Shop - 19th Jun 18
Minor Car Accident! What Happens After You Report Your Accident to Your Insurer - 19th Jun 18
US Majors Flush Out A Major Pivot Low and What’s Next - 18th Jun 18
Cocoa Commodities Trading Analysis - 18th Jun 18
Stock Market Consolidating in an Uptrend - 18th Jun 18
Russell Has Gone Up 7 Weeks in a Row. EXTREMELY Bullish for Stocks - 18th Jun 18
What Happens Next to Stocks when Tech Massively Outperforms Utilities and Consumer Staples - 18th Jun 18
The Trillion Dollar Market You’ve Never Heard Of - 18th Jun 18
The Corruption of Capitalism - 17th Jun 18
North Korea, Trade Wars, Precious Metals and Bitcoin - 17th Jun 18
Climate Change and Fish Stocks – Burning Oxygen! - 17th Jun 18
A $1,180 Ticket to NEW Trading Opportunities, FREE! - 16th Jun 18
Gold Bullish on Fed Interest Rate Hike - 16th Jun 18
Respite for Bitcoin Traders Might Be Deceptive - 16th Jun 18
The Euro Crashed Yesterday. Bearish for Euro and Bullish for USD - 15th Jun 18
Inflation Trade, in Progress Since Gold Kicked it Off - 15th Jun 18
Can Saudi Arabia Prevent The Next Oil Shock? - 15th Jun 18
The Biggest Online Gambling Companies - 15th Jun 18
Powell's Excess Reserve Change and Gold - 15th Jun 18
Is This a Big Sign of a Big Stock Market Turn? - 15th Jun 18
Will Italy Sink the EU and Boost Gold? - 15th Jun 18
Bumper Crash! Land Rover Discovery Sport vs Audi - 15th Jun 18
Stock Market Topping Pattern or Just Pause Before Going Higher? - 14th Jun 18
Is the ECB Ending QE a Good Thing? Markets Think So - 14th Jun 18
Yield Curve Continues to Flatten. A Bullish Sign for the Stock Market - 14th Jun 18
How Online Gambling has Impacted the Economy - 14th Jun 18
Crude Oil Price Targeting $58 ppb Before Finding Support - 14th Jun 18
Stock Market Near Another Top? - 14th Jun 18
Thorpe Park REAL Walking Dead Living Nightmare Zombie Car Park Ride Experience! - 14th Jun 18

Market Oracle FREE Newsletter

Category: BioTech

The analysis published under this category are as follows.

Companies

Thursday, May 03, 2018

4 Biotech Stock Movers to Watch / Companies / BioTech

By: Harry_Boxer

Biotechs continue to dominate our list of top charts to watch.

CASI Pharmaceuticals Inc. (CASI) rose 48 cents, or 7.2%, to $7.14 on 773,700 shares Tuesday. The move came on no news, although the stock soared in early April on news that China's Food and Drug Administration (CFDA) would convene a panel to discuss its cancer therapy, Evomela. The stock has been flagging since that move, but may be positioning to break out, with the next target at $10.

Read full article... Read full article...

 


Companies

Monday, September 11, 2017

Could This Be The Biggest Biotech Breakthrough Of The Year? / Companies / BioTech

By: OilPrice_Com

Someone dies of a stroke every 4 minutes in the United States. Globally, 15 million people suffer a stroke every year. It’s debilitating physically and financially—but one little-known company has developed a medical device that hopes to challenge that deadly statistic.

It’s been quietly developing this new technology for 10 years. Now it’s released updated preliminary clinical trial results, and signed a manufacturing deal which could make a significant impact in the medical device industry.

After a decade of painstaking development, we’re now nearing the end of the long road to validation, and for investors who understand this industry, this could be the critical juncture.

Read full article... Read full article...

 


Companies

Wednesday, July 19, 2017

Biotech with Alzheimer's Focus Makes Progress on Several Fronts / Companies / BioTech

By: TLSReport

In its corporate update for Q2/17, a Canada-based biotech targeting neurological disorders including Alzheimer's disease informed investors of advancements in several programs, including designation of a second validated lead compound in development.

Among ProMIS Neurosciences Inc.'s (PMN:TSE) "key accomplishments" in the quarter, the company noted it expanded its potentially "best in class amyloid-beta (Aβ) portfolio for Alzheimer's disease," according to a July 10 news release. In its oral presentation, the company stressed its emphasis on the "best in class" goal, noting that even though Biogen Inc.'s (BIIB:NASDAQ) aducanumab will be "first in class" and is progressing well in development, the ProMIS compound could be more selective and possess greater patient benefits.

Read full article... Read full article...

 


Companies

Sunday, April 23, 2017

After The Crash - Digital And Regenerative Medicine, Live for Ever! / Companies / BioTech

By: John_Rubino

For most people, the doctor visit hasn’t changed in decades. Same physical waiting rooms, same paper forms to fill out, same slow, expensive tests and marginally-effective, maximally-invasive treatments. But that’s about to change, as a wave of new technologies drag medicine into the 21st century. Among the most interesting:

Read full article... Read full article...

 


Companies

Tuesday, April 18, 2017

The Smart Money Is Piling Into Regenerative Medicine / Companies / BioTech

By: John_Mauldin

BY PATRICK COX : The Congressional Budget Office released its long-term budget outlook. This report should have sparked a national discussion about societal aging, but big media largely ignored it.

Fortunately, there are signs that smart investors are hedging this failure by investing in regenerative medicine (RM).

Read full article... Read full article...

 


Companies

Wednesday, April 05, 2017

British Billionaire Jim Mellon Says Biotech Is the Best Investment Now / Companies / BioTech

By: John_Mauldin

BY PATRICK COX : We are in the midst of an unprecedented change. Life spans have nearly doubled since the beginning of the 20th century. In addition, recent advances in computer technology have had a huge impact on biological sciences, which means this trend will accelerate.

Still, most people think that the process of aging will go on pretty much as it is now. They’re wrong.

Read full article... Read full article...

 


Companies

Monday, March 13, 2017

... / Companies / BioTech

By: OilPrice_Com

...

 


Companies

Tuesday, February 28, 2017

Major Funds Betting On Trump BioTech Sector / Companies / BioTech

By: TLSReport

Donald Trump's presidency is a real nitro boost for the future of the biotech sector in the U.S., says Tom Beck, editor of Portfolio Wealth Global.

Donald Trump's presidency is a massive boost to all industries, and is a real nitro boost for the future of the biotech sector in the U.S.

With 80 million baby-boomers looking to stay young and vital for a very long time, you should be making your move, and market-beating returns will be occurring from the large-cap stocks and in the small-cap sector even more so.

Read full article... Read full article...

 


Companies

Tuesday, January 24, 2017

The Last Time This Happened, Biotech Stocks Plunged by 50% / Companies / BioTech

By: John_Mauldin

BY PATRICK WATSON : “They’re getting away with murder,” said Donald Trump at last week’s epic news conference.

No, he didn’t mean Russian hackers. He was talking about red-blooded American drug companies.

Trump went on: “Pharma has a lot of lobbyists and a lot of power, and there is very little bidding. We’re the largest buyer of drugs in the world, and yet we don’t bid properly, and we’re going to save billions of dollars.”

Read full article... Read full article...

 


Companies

Wednesday, January 18, 2017

Biotech Breakthrough Could Create A $11.4 Trillion Opportunity / Companies / BioTech

By: OilPrice_Com

....

 


Companies

Saturday, December 03, 2016

Can Biotech's Trump Bump Last? / Companies / BioTech

By: TLSReport

In the weeks since Donald Trump's presidential election victory, the stock markets have ridden a wave into positive—and in the case of the Dow, record-breaking—territory. The so-called Trump Bump also sent biotech indices, flaccid for much of the year, up as much as 15%. With the election now nearly a month old, and hot-button issues such as drug pricing still in the press, industry watchers have begun to weigh in on what might happen in the biotech and pharma markets when Trump takes office.

Read full article... Read full article...

 


Economics

Monday, November 21, 2016

Trump Can Fix US Economy by Embracing Biotech / Economics / BioTech

By: John_Mauldin

BY PATRICK COX : The presidential campaign made one fact very clear. Most of the media and public aren't focused on economic growth.

Growth powers and funds everything else. Just take a look at the enormous federal deficit and you’ll see that economic health keeps taking a back seat to short-term goals.

Yes, John Maynard Keynes made a case for using debt to stimulate the economy. But he never said anything about permanent deficits. And that is our current practice. The result is that taxpayers’ options will be curtailed in the future.

Read full article... Read full article...

 


Companies

Thursday, November 03, 2016

The Rise in Infectious Diseases Means Opportunity for Biotech Investors / Companies / BioTech

By: John_Mauldin

BY PATRICK COX : The CDC has expanded its count of Miami neighborhoods with verified local transmission of the Zika virus. As a result, pregnant women are taking precautions. Some have left the area. Others are donning hazmat suits.

At least one case of locally acquired Zika has been confirmed on Florida’s Gulf Coast where I live, and there are probably more. This is because most people don’t know that they’ve been infected and are carriers.

Read full article... Read full article...

 


Companies

Wednesday, September 21, 2016

Imagin, a Better Way to Detect Bladder Cancer / Companies / BioTech

By: TLSReport

Bob Moriarty profiles Imagin Medical, a company that has developed a new way of detecting bladder cancer through endoscopes.

The most common cancers in the U.S. are hardly the most expensive to treat. More Americans come down with breast cancer and lung cancer than any other types of cancer. The worst cancer from a perspective of expense turns out to be bladder cancer that is only the 6th most prevalent form of disease.

Read full article... Read full article...

 


Stock-Markets

Thursday, September 15, 2016

Great Day for Biotech Stocks / Stock-Markets / BioTech

By: Harry_Boxer

The stock market indices rebounded smartly in the morning, but got up to overhead resistance, particularly on the Nasdaq 100, which failed several times trying to get through 4770. At that point, the S&P 500 was trailing badly. They then went into an afternoon decline, and orderly retraced channel, 5-wave decline on the S&P 500, and then dropped right back to the 2120 level it reached twice in three days. This was the third test. That was successful. It bounced a few points off that level. It was not exactly a rip-roaring rally, but, nevertheless, support held for now, with the S&P 500 having a triple bottom, and the Nasdaq 100 having a right-handed, extended V-pattern, or rising wedge. No question with overhead resistance at 4770, or thereabouts on the Nasdaq 100, as well as for starters 2140-5 zone on the S&P 500 is going to be critical going forward.

Read full article... Read full article...

 


Companies

Wednesday, June 08, 2016

Investment in Cell and Gene Therapies Ramps Up / Companies / BioTech

By: TLSReport

After decades of disappointment, cell therapies and gene therapies are finally seeing light at the end of the tunnel. Investors, investigators, clinicians, and patients with serious unmet needs are watching pivotal trials move into the home stretch. Yes. . .pivotal data are actually on the way.

Though the roadblocks that have held back development of cell and gene therapies since the mid-1990s have been expensive in terms of a lingering hangover with depressed valuations, investors are now looking at achievement in terms of meaningful endpoints.

Read full article... Read full article...

 


Companies

Tuesday, June 07, 2016

Detecting Cancer With White and Blue Light / Companies / BioTech

By: Richard_Mills

Endoscopy is often used in the prevention, early detection, diagnosis, staging, and treatment of cancer.

X-rays and CT scans can show physical changes within the body and give information about the size, shape, and location of the changes. Endoscopes show details like color and surface texture allowing doctors to see exactly what’s going on.

If you go to a doctor exhibiting certain symptoms, endoscopy could be used to find the cause:

Read full article... Read full article...

 


Companies

Thursday, April 07, 2016

IBB (Biotech ETF) Baby Bull Market / Companies / BioTech

By: Gary_Savage

Here we go again. Remember when I warned traders not to short the baby bull in miners and exhorted them to not lose their position because surprises would come to the upside? Needless to say, many ignored that advice and they cost themselves dearly.

Now we have a second baby bull just getting started in Biotech. It still has a long ways to go. Yet I’m seeing some traders making the same mistakes again.

Read full article... Read full article...

 


Companies

Thursday, March 10, 2016

Seven Small-Cap Biotech Stocks on the Upswing 2016 / Companies / BioTech

By: TLSReport

Biotech stocks—and the stock market in general—took a dive at the beginning of 2016, headed down on macroeconomic factors such as financial instability in China. The Life Sciences Report's 2016 Small-Cap Biotech Watchlist was not immune to that movement, heading into negative territory almost from the moment the selected companies were introduced. But as the market has shown signs of rebounding, so too has the Watchlist.

Read full article... Read full article...

 


Companies

Thursday, February 04, 2016

Look North for Value-Priced Growth in Healthcare Biotech Stocks / Companies / BioTech

By: TLSReport

Canada is a wellspring for natural resources and the industries built around them. But the country also encompasses healthcare-related businesses that are growing, generating cash flow and flourishing. Bruce Campbell of StoneCastle Investment Management has managed both U.S. and Canadian portfolios, and he knows both spheres. As a hedge fund and mutual fund manager concentrating on Canadian companies, he has made a specialty in acquisitions of cash-generating healthcare companies. In this interview with The Life Sciences Report, Campbell discusses seven small-cap growth names, all of which have reached share-price levels that do not reflect their capacity to grow. Some may offer rare opportunities to buy at risk-mitigated value prices.

Read full article... Read full article...

 


Page << | 1 | 2 | 3 | 4 | >>